bhosle deepak (8 resultados)

Condición: New.

Taschenbuch. Condición: Neu. Effect of Metrofim and Vildagliptin in Type II diabetes | Vildagliptin a new drug treatment for Type II Diabetes | Deepak Bhosle (u. a.) | Taschenbuch | 104 S. | Englisch | 2012 | LAP LAMBERT Academic Publishing | EAN 9783659257858 | Verantwortliche Person für die EU: BoD - Books on Demand, In de Tarpen 42, 22848 Norderstedt, info[at]bod[dot]de | Anbieter: preigu.

Taschenbuch. Condición: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Diabetes mellitus is a group of metabolic disorder characterized by hyperglycaemia and altered metabolism of lipid, protein and carbohydrate. In diabetes there is total or subtotal deficiency of insulin along incetine defice.Insulin and many oral hypoglycemic drugs and are available for the treatment of Type II still target HbA1c is not achived. Vildaglipton selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of circulating Glucagon - like Peptide-1.It improves islet function in patients with type-2 diabetes by increasing both and cell responsiveness to glucose and decrease fasting plasma glucose (FPG) and postprandial glucose.Metformin is the most commonly prescribed first-line hypoglycaemic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type-2 diabetes, combination therapy usually becomes necessary.Therefore, it was of interest to ascertain the efficacy and tolerability of Vildagliptin, Metformin alone and in combination of both in type-2 diabetic patients.We got encouraging result with combination. 104 pp. Englisch.

Condición: New. Print on Demand.

Condición: New. PRINT ON DEMAND.

Condición: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Autor/Autorin: Bhosle DeepakDr.Deepak Bhosle is consultant diabetologist and practicing in the Aurangabad, India.He is also Professor and Head of the Department of Pharmacology in Mahatma Gandhi Mission Hospital Aurangabad Since 2003.He having seve.

Taschenbuch. Condición: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Diabetes mellitus is a group of metabolic disorder characterized by hyperglycaemia and altered metabolism of lipid, protein and carbohydrate. In diabetes there is total or subtotal deficiency of insulin along incetine defice.Insulin and many oral hypoglycemic drugs and are available for the treatment of Type II still target HbA1c is not achived. Vildaglipton selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of circulating Glucagon - like Peptide-1.It improves islet function in patients with type-2 diabetes by increasing both ¿ and ß cell responsiveness to glucose and decrease fasting plasma glucose (FPG) and postprandial glucose.Metformin is the most commonly prescribed first-line hypoglycaemic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type-2 diabetes, combination therapy usually becomes necessary.Therefore, it was of interest to ascertain the efficacy and tolerability of Vildagliptin, Metformin alone and in combination of both in type-2 diabetic patients.We got encouraging result with combination.VDM Verlag, Dudweiler Landstraße 99, 66123 Saarbrücken 104 pp. Englisch.

Taschenbuch. Condición: Neu. nach der Bestellung gedruckt Neuware - Printed after ordering - Diabetes mellitus is a group of metabolic disorder characterized by hyperglycaemia and altered metabolism of lipid, protein and carbohydrate. In diabetes there is total or subtotal deficiency of insulin along incetine defice.Insulin and many oral hypoglycemic drugs and are available for the treatment of Type II still target HbA1c is not achived. Vildaglipton selective inhibitor of Dipeptidyl Peptidase-4 (DPP-4), the enzyme responsible for the rapid degradation of circulating Glucagon - like Peptide-1.It improves islet function in patients with type-2 diabetes by increasing both and cell responsiveness to glucose and decrease fasting plasma glucose (FPG) and postprandial glucose.Metformin is the most commonly prescribed first-line hypoglycaemic drug worldwide, but due to the progressive worsening of blood glucose control during the natural history of type-2 diabetes, combination therapy usually becomes necessary.Therefore, it was of interest to ascertain the efficacy and tolerability of Vildagliptin, Metformin alone and in combination of both in type-2 diabetic patients.We got encouraging result with combination.